uniQure Announces Financial Results For Second Quarter 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress

~ Progress Across the Pipeline ~ Additional data on AMT-060 in Hemophilia B Expected Later this Year ~Data from Sanfilippo B and Parkinson's Disease Studies Expected in Q1 2017 ~Strong Balance Sheet to Support Advancement of Programs

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 25, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced its financial results for the second quarter, ended June 30, 2016, and provided an update on corporate developments.

"We continue to make solid progress on our pipeline programs and are pleased to maintain a strong cash position that will enable us to advance our product candidates well into the future," stated Daniel Soland, chief executive officer of uniQure. "We presented promising updated clinical data from the low-dose cohort of our ongoing Phase I/II study of AMT-060, which demonstrated durable, therapeutically relevant Factor IX activity in older patients with severe hemophilia B and advanced joint disease.  Importantly, we expect to present up to one year of follow-up data from our low dose cohort and up to 6 months of follow-up data from our second dose cohort of AMT-060 later this year.  Additionally, we look forward to clinical data presentations from studies in Sanfilippo B and Parkinson's disease in the first quarter of 2017."

Recent Corporate Highlights

Pipeline and Business Updates

Liver/Metabolic Diseases

  • Advancing AMT-060 in Hemophilia B - uniQure presented updated results from its ongoing Phase I/II clinical trial of AMT-060 in patients with severe hemophilia B and advanced joint disease at the World Federation of Hemophilia Congress. The clinical data from the low-dose cohort showed sustained Factor IX (FIX) activity and a substantial reduction in FIX usage. All patients had improvements in their disease phenotype and continued to maintain durable levels of FIX activity for up to 9 months post treatment.  Four out of five patients remained free of prophylactic FIX usage with mean steady-state FIX activity of 5.4% of normal and an 82% reduction in total FIX usage through up to 9 months.  Of note , AMT-060 continues to demonstrate a very low screening failure rate, with all patients screened in the study testing negative for pre-existing anti-AAV5 antibodies. All five patients in the second-dose cohort have now been treated, with 6-month data expected to be available for presentation later this year.    

Central Nervous System (CNS) Diseases

  • Ongoing Follow-up of AMT-110 in Sanfilippo B - uniQure anticipates that all four patients in this Phase I/II extension study will have completed their 30-month evaluation late this year and that clinical data will be presented in the first quarter of 2017.  uniQure assumed sponsorship of the Phase I/II study extension protocol earlier this year.
  • Advancing Preclinical Research of AMT-130 in Huntington's Disease - uniQure is conducting ongoing IND-enabling studies of AMT-130 in non-human primates.  Earlier this year, uniQure published and presented data providing preclinical proof-of-concept and demonstrating the potential of a one-time administration of AAV5-delivered gene therapy to successfully silence the Huntingtin gene.   
  • Continued Progress on Phase I/IIa Study of AMT-140 in Parkinson's Disease - Two of the four, six-patient cohorts have now been fully enrolled since June 2016 in an ongoing Phase I/IIa clinical study of AMT-140, an AAV2-GDNF gene therapy for the treatment of Parkinson's disease.  Top-line data, including safety, tolerability and preliminary efficacy results, are expected to be available for presentation in the first quarter of 2017.  The study is being conducted under the direction of Krystof Bankiewicz at the University of California, San Francisco (UCSF) and John Heiss at the National Institutes of Health.  uniQure has exclusive rights to GDNF in gene therapy and has the option to acquire the program from UCSF. 

Cardiovascular Diseases

  • Increasing Activity in Support of BMS Collaboration - uniQure and its collaboration partner, Bristol Myers Squibb (BMS), continue to conduct IND-enabling studies for S100A1, a proprietary gene therapy for chronic heart failure.  In addition to S100A1, uniQure and BMS have initiated work on 3 additional targets designated under their collaboration. 

Leadership Team and Board of Directors

  • Added Key Talent - In the second quarter, uniQure significantly strengthened its senior management team with the appointment of Paul Firuta as Chief Commercial Officer, Hans Janssen as Senior Vice President, Human Resources, Maria E. Cantor as Senior Vice President, Investor Relations & Communications, and Jonathan Garen as Chief Business Officer.  
  • Completed Corporate Governance Changes - Following its Annual General Meeting in June, the Company transitioned from a two-tier Supervisory Board and Management Board to a single Board of Directors structure with executive and non-executive members. This new structure reflects corporate governance standards most familiar to the majority of the Company's shareholder base. In addition, the Company appointed Jack Kaye, a seasoned financial executive with more than 40 years of diversified experience, to its Board of Directors.  Company shareholders also approved the appointments of Daniel Soland, chief executive officer, and Matthew Kapusta, chief financial officer, as executive directors of the Board.  Finally, as part of the governance transition, Mr. Ferdinand Verdonck and Mr. Joseph Fezcko retired from the board.

Business Development

  • In the second quarter, uniQure revised its existing license contract with Protein Sciences Corporation for the use of its expres SF+ (SF+) insect cell line to provide the Company with a royalty free, perpetual right and license to the licensed technology in the field of AAV-based gene therapy.

Financial Highlights for Q2 2016 

As of June 30, 2016, the Company held cash and cash equivalents of €165.6 million, compared with of €203.5 million as of December 31, 2015, a decrease of €37.9 million. The decrease includes €36.4 million of cash used in operating, investing and financing activities during the six months ended June 30, 2016, in addition to a €1.5 million loss related to foreign currency effects on U.S. dollar-denominated deposits. The Company maintains its expectation that existing cash resources will be sufficient to fund operations into the second half of 2018.   

Licensing and collaboration revenues for the three months ended June 30, 2016 were €3.9 million, compared with €1.6 million for the comparable period in 2015. The increase relates to increased research activity associated with S100A1 for heart failure, which are fully reimbursed by BMS in accordance with the Company's collaboration agreement.

Research and development expenses were €17.3 million for the three months ended June 30, 2016, compared with €10.6 million for the comparable period in 2015. The increase is mainly due to increased activity in support of our collaboration agreement with BMS, validation and scale-up activities related to AMT-060 in the Company's Lexington facility, increased facility costs in Amsterdam and the continued progression of our gene therapy product candidates targeting Sanfillippo B, Huntington's disease and hemophilia A.           

Selling, general and administrative expenses were €5.5 million for the three months ended June 30, 2016, compared with €4.5 million for the comparable period in 2015. The change is primarily related to an increase in personnel expense, as well as an increase in expenses associated with the Glybera global registry and Phase IV study, which are currently classified as selling, general and administrative expenses, but were previously capitalized in the same period in 2015 prior to the commencement of Glybera commercialization.

The net loss for the second quarter 2016 was €19.3 million, or €0.77 per share, compared with €18.9 million, or €0.87 per share, for the second quarter of 2015. The Company had 25,137,009 ordinary shares outstanding as of June 30, 2016.

About uniQure uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com

uniQure Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators' clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

Maria E. Cantor Direct: 339-970-7536 Mobile:  617-680-9452 m.cantor@uniQure.com

Eva Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 e.mulder@uniQure.com

UNIQURE N.V. Unaudited Condensed Consolidated Statement of Financial Position (€ in thousands)

    December 31,   June 30,
  2015   2016
Assets        
Non-current assets        
Goodwill   442   442
Intangible assets other than Goodwill   7,209   8,956
Property, plant and equipment   23,820   24,041
Other non-current assets   1,142   1,675
Total non-current assets   32,613   35,114
Current assets        
Receivables from related parties   3,792   1,502
Trade and other receivables   1,730   5,195
Inventories   435   363
Cash and cash equivalents   203,532   165,646
Total current assets   209,489   172,706
Total assets   242,102   207,820
Equity        
Share capital   1,216   1,257
Share premium   344,803   346,732
Other reserves   26,026   29,785
Accumulated deficit    (252,561)    (292,468)
Total equity   119,484   85,306
Liabilities        
Non-current liabilities        
Borrowings   13,434   18,356
Derivative financial instruments  - related party   530   136
Deferred rent   5,737   5,789
Deferred revenue   75,852   73,507
Contingent consideration   2,687   2,915
Total non-current liabilities   98,240   100,703
Current liabilities        
Trade and other payables   11,220   12,568
Derivative financial instruments - related parties   992   222
Borrowings   5,124   -
Borrowings - derivative   238   51
Deferred rent   579   592
Deferred revenue   6,225   5,978
Provisions   -   2,400
Total current liabilities   24,378   21,811
Total liabilities   122,618   122,514
Total equity and liabilities   242,102   207,820

UNIQURE N.V. Unaudited Condensed Consolidated Statements of Comprehensive Income (€ in thousands except share and per share data)

  Three months ended   Six months ended
  June 30,   June 30,
               
2015   2016   2015   2016
License revenues 492   1,101   713   2,202
Collaboration revenues 1,123   2,840   2,009   5,641
Total revenues 1,615   3,941   2,722   7,843
Cost of goods sold -    (76)   -    (152)
Other income 140   423   346   824
Research and development expenses  (10,613)    (17,335)    (20,719)    (32,463)
Selling, general and administrative expenses  (4,509)    (5,504)    (8,668)    (12,108)
Other gains/(losses), net  (5,241)    (321)    (996)    (4,379)
Total operating costs  (20,223)    (22,813)    (30,037)    (48,278)
Operating loss  (18,608)    (18,872)    (27,315)    (40,435)
Finance income 46   64   65   1,584
Finance expense  (325)    (523)    (4,275)    (1,056)
Finance income/(expense), net  (279)    (459)    (4,210)   528
Result before corporate income tax (18,887)   (19,331)   (31,525)   (39,907)
Provision for income taxes -   -   -   -
Net loss  (18,887)    (19,331)    (31,525)    (39,907)
Items that may be subsequently reclassified to profit or loss              
Currency translation differences on foreign operations  (285)   356   1,086    (301)
Other comprehensive income/(loss)  (285)   356   1,086    (301)
Total comprehensive loss  (19,172)    (18,975)    (30,439)    (40,208)
Loss per share attributable to the equity holders of the              
Company during the period:              
Basic and diluted loss per share  (0.87)    (0.77)    (1.58)    (1.60)

UNIQURE N.V. Unaudited Condensed Consolidated Statements of Changes in Equity/Deficit (€ in thousands)

    Total                
    share   Share   Other   Accumulated   Total
    capital   premium   reserves   deficit   equity
Balance at January 1, 2015   905   206,111   17,149    (181,081)   43,084
Loss for the period   -   -   -    (31,525)    (31,525)
Other comprehensive income/(loss)   -   -   1,086   -   1,086
Total comprehensive income/(loss)   -   -   1,086    (31,525)    (30,439)
Capital contributions   231   101,747   -   -   101,978
Share issuance costs   -    (612)   -   -    (612)
Share based payment/expense   -   -   3,416   -   3,416
Balance at June 30, 2015   1,136   307,246   21,651    (212,606)   117,427
Loss for the period   -   -   -    (39,955)    (39,955)
Other comprehensive income/(loss)   -   -   164   -   164
Total comprehensive income/(loss)   -   -   164    (39,955)    (39,791)
Capital contributions   80   37,557   -   -   37,637
Share based payment/expense   -   -   4,211   -   4,211
Balance at December 31, 2015   1,216   344,803   26,026    (252,561)   119,484
Loss for the period   -   -   -    (39,907)    (39,907)
Other comprehensive income/(loss)   -   -    (301)     -    (301)
Total comprehensive income/(loss)   -   -    (301)    (39,907)    (40,208)
Capital contributions   41   1,929   -   -   1,970
Share based payment/expense   -   -   4,060   -   4,060
Balance at June 30, 2016   1,257   346,732   29,785    (292,468)   85,306

UNIQURE N.V. Unaudited Condensed Consolidated Statements of Cash Flows (€ in thousands)

  Six months ended
  June 30,
       
  2015   2016
Cash flow from operating activities      
Net loss  (31,525)    (39,907)
Adjustments for:      
Amortization on intangible assets -   378
Depreciation 1,877   2,462
Lease incentive 333    (398)
Loss/(gain) on derivatives 1,666    (1,351)
Loss/(gain) on foreign exchanges 1,873   1,280
Share-based expenses 3,416   4,060
Changes in provisions -   2,400
Changes in trade and other receivables  (1,363)    (1,174)
Changes in inventories  (214)   72
Changes in other current liabilities  (232)   810
Changes in deferred revenue 52,769    (2,592)
Cash generated from/(used in) operations 28,600    (33,960)
Interest paid  (929)    (1,006)
Net cash generated from/(used in) operating activities 27,671    (34,966)
Cash used in investing activities      
Purchases of intangible assets  (1,729)    (10)
Purchases of property, plant and equipment  (1,855)    (2,776)
Changes in restricted cash -    (555)
Interest received 59   33
Net cash used in investing activities  (3,525)    (3,308)
Cash flow from financing activities      
Proceeds from shares issued 101,366   1,970
Payments of finance lease  (82)    (88)
Net cash generated from financing activities 101,284   1,882
Net increase/(decrease) in cash and cash equivalents 125,430    (36,392)
Currency effect cash and cash equivalents 3,206    (1,494)
Cash and cash equivalents at January 1 53,219   203,532
Cash and cash equivalents at June 30 181,855   165,646
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 152

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 193

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 75

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 208

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 15

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 142

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 108

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 79

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 195

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading

Top 5 Most Recently Viewed Articles

Enveric Biosciences Expands Patent Portfolio for Drug Development

Updated Category News Views 76

Enveric Biosciences Expands Patent Protection for EVM301 Portfolio Enveric Biosciences (NASDAQ: ENVB) is making remarkable strides in the biotechnology sector with its commitment to developing novel neuroplastogens aimed at treating neuropsychiatric disorders. This dedication has led to the expansion of its patent portfolio with the issuance of five new U.S. patents, as...

Continue Reading
DTCC Enhances Global Operations with New Hyderabad Office

Updated Category News Views 394

DTCC Expands Horizons with New Office in Hyderabad The Depository Trust & Clearing Corporation (DTCC), a key player in post-trade market infrastructures for the global financial services sector, recently celebrated the grand opening of its new office in Hyderabad, India. This expansion underscores the company’s strategic commitment to enhancing its capabilities in a...

Continue Reading
Overview of Ericsson's Annual General Meeting in 2025

Updated Category News Views 231

Ericsson's Annual General Meeting Highlights Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) held its Annual General Meeting (AGM) in Kista, focusing on significant corporate matters that impact shareholders and the company's strategic direction. This meeting provided an essential platform for stakeholders to participate in decision-making processes, even offering postal...

Continue Reading
Prospera Energy Inc. Optimizes Production with Recent Updates

Updated Category News Views 430

Prospera Energy Inc. Optimizes Production Strategies CALGARY, Alberta - Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) is making significant strides in enhancing its operational efficiency and expanding its energy production capabilities. In an exciting update, the Corporation has provided crucial insights into its recent service rig operations, successful acquisitions,...

Continue Reading
Exploring Growth in the Clean Label Ingredients Industry

Updated Category News Views 287

The Clean Label Ingredients Market: A New Era of Transparency The global clean label ingredients market is flourishing as consumers increasingly seek natural food products. With the demand for preservative-free and organic food additives on the rise, the food industry is shifting dramatically. This transformation centers on enhancing transparency in food labeling and...

Continue Reading